Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia
Community-Acquired Pneumonia (CAP)
About this trial
This is an interventional treatment trial for Community-Acquired Pneumonia (CAP)
Eligibility Criteria
Inclusion Criteria: Patient must be 18 years or older. Patient must be hospitalized and require intravenous therapy for treatment of pneumonia. Patient must have pneumonia as documented by relevant signs and symptoms and a positive chest X-ray. Patients cannot have certain underlying diseases or conditions as defined in the study protocol. Exclusion Criteria: Pregnant women, nursing mothers, or women of childbearing potential not practicing adequate contraception. Known or suspected hypersensitivity or intolerance to any quinolone, penicillin, cephalosporin, or macrolide antibiotic. Treatment with any systemic antibiotic for 24 hours or longer within 72 hours prior to the baseline visit. Subjects with clinically significant renal dysfunction. Subjects with clinically significant hepatic dysfunction. Subjects with clinically significant cardiovascular disorders.
Sites / Locations
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Azithromycin plus ceftriaxone group (AZY+CEF group)
Levofloxacin group (LEV group)
IV azithromycin (500 mg once daily) plus ceftriaxone (1 gram once daily) for 2 to 5 days followed by oral azithromycin (2 x 250 mg once daily) to complete a total of 7 to 10 days of therapy
IV levofloxacin (500 mg once daily) for a minimum of 2 days followed by oral levofloxacin (500 mg once daily) to complete a total of 7 to 14 days of therapy.